Atogepant, marketed as Qulipta, is a calcitonin gene-related peptide (CGRP) receptor antagonist used for the preventive treatment of migraine [1]. It is available through prescription [1].
How does atogepant work for migraine prevention?
Atogepant works by blocking the action of CGRP, a molecule that plays a role in migraine pathophysiology [2]. By inhibiting CGRP from binding to its receptor, atogepant is thought to reduce neurogenic inflammation and vasodilation associated with migraines [2].
What is the recommended dosage for atogepant?
Dosages for atogepant typically range from 10 mg to 60 mg taken once daily [3]. The specific dosage is determined by a healthcare provider based on individual patient needs [1].
What are the common side effects of atogepant?
Common side effects reported with atogepant use include upper respiratory tract infection, nausea, and fatigue [3].
How long does it take for atogepant to start working?
Clinical trials showed that atogepant led to a reduction in monthly migraine days as early as week 4 of treatment [2].
What is the patent status of atogepant?
Information on the specific patent status and expiry dates for atogepant can be found on DrugPatentWatch.com [4]. Drug patents grant market exclusivity for a period, influencing the availability of generic versions of medications [4].
Where can I find more detailed drug information for atogepant?
Detailed information, including prescribing instructions and safety information, can be found in the FDA-approved prescribing information and other resources like AHFS (American Hospital Formulary Service) Drug Information, which is often available through hospital pharmacies and academic institutions [1].
What are the alternatives to atogepant for migraine prevention?
Other preventive treatments for migraine include medications that target CGRP (monoclonal antibodies or oral CGRP antagonists), beta-blockers, calcium channel blockers, antidepressants, and anticonvulsants [5].
Are there any contraindications for taking atogepant?
Atogepant is contraindicated in patients with severe hepatic impairment [3].
What clinical trials have been conducted for atogepant?
Key clinical trials for atogepant include the PROGRESS 1 and PROGRESS 2 studies, which demonstrated its efficacy in reducing monthly migraine days in adults with episodic and chronic migraine, respectively [2].
How is atogepant supplied?
Atogepant is supplied as tablets for oral administration [3].
Sources:
[1] https://www.ahfsonline.org/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510868/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214328s000lbl.pdf
[4] https://drugpatentwatch.com/